Alector (NASDAQ:ALEC) CFO Neil Lindsay Berkley Sells 37,261 Shares of Stock

Alector, Inc. (NASDAQ:ALEC) CFO Neil Lindsay Berkley sold 37,261 shares of the firm’s stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $1.12, for a total transaction of $41,732.32. Following the sale, the chief financial officer owned 374,309 shares of the company’s stock, valued at approximately $419,226.08. This represents a 9.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Alector Trading Up 0.4%

Shares of NASDAQ ALEC opened at $1.15 on Thursday. The firm’s 50 day moving average price is $2.01 and its 200-day moving average price is $1.94. Alector, Inc. has a 52-week low of $0.87 and a 52-week high of $3.40. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.76 and a current ratio of 3.76. The company has a market cap of $124.98 million, a PE ratio of -1.05 and a beta of 0.67.

Alector (NASDAQ:ALEC) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.08. The business had revenue of $3.26 million for the quarter, compared to analysts’ expectations of $3.49 million. Alector had a negative return on equity of 123.02% and a negative net margin of 156.03%. On average, equities research analysts expect that Alector, Inc. will post -1.88 EPS for the current fiscal year.

Institutional Trading of Alector

A number of large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its position in shares of Alector by 1.8% during the 2nd quarter. Bank of America Corp DE now owns 343,909 shares of the company’s stock valued at $481,000 after acquiring an additional 5,927 shares during the last quarter. Los Angeles Capital Management LLC lifted its position in Alector by 5.3% during the second quarter. Los Angeles Capital Management LLC now owns 151,896 shares of the company’s stock valued at $213,000 after purchasing an additional 7,600 shares during the last quarter. Vontobel Holding Ltd. grew its stake in shares of Alector by 26.7% in the 2nd quarter. Vontobel Holding Ltd. now owns 38,000 shares of the company’s stock worth $53,000 after buying an additional 8,000 shares in the last quarter. Sio Capital Management LLC raised its position in shares of Alector by 1.0% during the 2nd quarter. Sio Capital Management LLC now owns 845,531 shares of the company’s stock valued at $1,184,000 after buying an additional 8,372 shares in the last quarter. Finally, Mackenzie Financial Corp increased its stake in Alector by 3.4% during the third quarter. Mackenzie Financial Corp now owns 283,712 shares of the company’s stock worth $840,000 after acquiring an additional 9,270 shares during the last quarter. Institutional investors own 85.83% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on ALEC shares. Cantor Fitzgerald downgraded shares of Alector from an “overweight” rating to a “neutral” rating in a research report on Wednesday, October 22nd. Wall Street Zen cut Alector from a “hold” rating to a “sell” rating in a research report on Friday, November 28th. BTIG Research cut Alector from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 22nd. William Blair cut shares of Alector from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 22nd. Finally, Mizuho set a $1.50 price target on shares of Alector and gave the stock a “neutral” rating in a research report on Wednesday, October 22nd. One analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Reduce” and a consensus target price of $3.40.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.